ArticleNature2019
NR4A transcription factors limit CAR T cell function in solid tumours.
Registry-linked trialOpen access · greenAbstract read
In one paragraph
Article in Nature, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03941496 (Phase 1b/2a Safety and Immunogenicity of the DNMT Inhibitor Azacitidine During Anti-Tuberculosis Therapy), which is not on this map. Cited by 583 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
583citing papers in PubMed, 2 pooled it
37.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT03941496 phase1 / phase2withdrawnnot on this mapstarted 2022, after this paper: background citation
Phase 1b/2a Safety and Immunogenicity of the DNMT Inhibitor Azacitidine During Anti-Tuberculosis Therapy
Who cites it
583 citing papers in PubMed, 2 syntheses or guidelines pooled it, 809 citations in OpenAlex.
- Mapping the clinical landscape of multifunctional CAR T cells: Targets, trends, and synergies.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Pooled it
- Strategies and mechanisms for the enhancement of chimeric antigen receptor T-cell functions.Science China. Life sciences · 2026Pooled it
- Effect of the mitophagy inducer urolithin A on age-related immune decline: a randomized, placebo-controlled trial.Nature aging · 2025Trial
- The LXRβ/NF-κB axis reprograms CAR-T cells to resist exhaustion in the tumor microenvironment.Oncoimmunology · 2026Article
- Article
- Targeting myeloid cell plasticity and metabolic reprogramming to alleviate T cell dysfunction and exhaustion-associated states and enhance immune checkpoint blockade therapy.Biomarker research · 2026Review
- SUMO2 deletion changes chromatin accessibility and enhances cytotoxic T cell activation and tumor infiltration.Science advances · 2026Article
- CRISPR in clinical oncology: translational advances from molecular diagnostics to therapeutics.Nature reviews. Clinical oncology · 2026Review
- Barriers and Blueprints: Next-Generation Engineering Strategies for CAR-T Cell Therapy in Gastrointestinal Tumors.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Identification of novel paracrine therapeutic targets in peritoneal metastases through integrative proteotranscriptomic analysis of ascites.Molecular cancer · 2026Article
- Recent advances in molecular mechanisms to improve the efficacy of CAR-T cell therapy for viral diseases, cancer, and autoimmune diseases.Stem cell research & therapy · 2026Review
- T cell senescence and exhaustion: molecular mechanisms and immune rejuvenation for cancer immunotherapy.Signal transduction and targeted therapy · 2026Review
- Explainable machine learning and multimodal single cell analysis link NR4A2 to CD8Journal, genetic engineering & biotechnology · 2026Article
- Adoptive cell therapy in lung cancer: progress, challenges, and prospects.Chinese medical journal pulmonary and critical care medicine · 2026Review
- PROTAC-mediated targeting of IKKβ and NR4A1 for AML therapy.Oncogene · 2026Article
- Clonal sharing and plasticity of follicular CD4 + T cells across lymph nodes and tumors in non-small cell lung cancer.Nature communications · 2026Article
- The transcription factor IRF8 drives tumor-specific exhaustion in CD8+ T cells.The Journal of experimental medicine · 2026Article
- Cancer Immunotherapy: Therapeutic Limitations and Next-Generation Precision Strategies.Immune network · 2026Review
- A guide to CAR T cell therapies: development, current status and future prospects.Nature reviews. Immunology · 2026Review
- PARK7-induced delactylation of ATAD3A impairs mitochondrial fitness to promote exhaustion of tumor-infiltrating CD8Cellular & molecular immunology · 2026Article
523 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
9 authors at 5 institutions in 2 countries.
Joyce ChenDivision of Signaling and Gene Expression, La Jolla Institute for Immunology, La Jolla, CA, USA. jchen@lji.org.
Isaac F López-MoyadoDivision of Signaling and Gene Expression, La Jolla Institute for Immunology, La Jolla, CA, USA.
Hyungseok SeoDivision of Signaling and Gene Expression, La Jolla Institute for Immunology, La Jolla, CA, USA.
Chan-Wang J LioDivision of Signaling and Gene Expression, La Jolla Institute for Immunology, La Jolla, CA, USA.
Laura J HemplemanDivision of Signaling and Gene Expression, La Jolla Institute for Immunology, La Jolla, CA, USA.
Takashi SekiyaDepartment of Immune Regulation, National Center for Global Health and Medicine, Ichikawa, Chiba, Japan.
Akihiko YoshimuraDepartment of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan.
James P Scott-BrowneDivision of Signaling and Gene Expression, La Jolla Institute for Immunology, La Jolla, CA, USA. ScottBrownej@njhealth.org.
Anjana RaoDivision of Signaling and Gene Expression, La Jolla Institute for Immunology, La Jolla, CA, USA. arao@lji.org.
La Jolla Institute for Immunology · USKeio University · JPNational Center for Global Health and Medicine · JPSanford Consortium for Regenerative Medicine · USUniversity of California, San Diego · US
Funding
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007198 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHI, NEIL C, INSEL, PAUL A · 1985 to 2024
$29.3MGRADUATE TRAINING IN CELLULAR &MOLECULAR PHARMACOLOGYT32GM007752 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BROWN, JOAN HELLER, HANDEL, TRACY M · 1985 to 2023
$13.5MSIGNAL TRANSDUCTION AND GENE INDUCTION IN T LYMPHOCYTESR01AI040127 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI HOGAN, PATRICK, RAO, ANJANA · 1996 to 2025
$13.3MNFAT, bZIP proteins, and transcriptional programs in lymphocytesR01AI109842 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI Patrick Hogan, Anjana Rao · 2014 to 2026
$8.6MTRANSCRIPTIONAL MECHANISMS UNDERLYING TOLERANCER01AI048213 · NIAID · IMMUNE DISEASE INSTITUTE, INC. · PI RAO, ANJANA · 2000 to 2009
$5.2MStimulating Neo-Antigen Specific T Cell Responses in Head and Neck CancersU01DE028227 · NIDCR · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI GUTKIND, JORGE SILVIO, RAO, ANJANA · 2018 to 2022
$4.6MIllumina HiSeq 2500 Sequencing SystemS10OD016262 · OD · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI RAO, ANJANA · 2013 to 2013
$600kFACSAria II Cell SorterS10RR027366 · NCRR · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI CROFT, MICHAEL · 2011 to 2011
$514kNFAT, bZIP proteins, and transcriptional programs in lymphocytesR56AI109842 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI HOGAN, PATRICK, RAO, ANJANA · 2019 to 2019
$414kNCRR NIH HHS S10 RR027366NIAID NIH HHS R01 AI040127NIAID NIH HHS R01 AI048213NIAID NIH HHS R01 AI109842NIAID NIH HHS R56 AI109842NIDCR NIH HHS U01 DE028227NIGMS NIH HHS T32 GM007752NIH HHS S10 OD016262
Abstract
T cells expressing chimeric antigen receptors (CAR T cells) targeting human CD19 (hCD19) have shown clinical efficacy against B cell malignancies
Indexed as
Adoptive TransferAnimalsAntigens, CD19CD8-Positive T-LymphocytesCell Line, TumorChromatinDNA-Binding ProteinsFemaleGene Expression ProfilingHumansLymphocytes, Tumor-InfiltratingMaleMelanoma, ExperimentalMiceMice, Inbred C57BLNeoplasmsAntigens, CD19CD19 molecule, humanChromatinDNA-Binding ProteinsNF-kappa BNR4A1 protein, humanNR4A2 protein, humanNR4A3 protein, humanNuclear Receptor Subfamily 4, Group A, Member 1Nuclear Receptor Subfamily 4, Group A, Member 2Receptors, Chimeric AntigenReceptors, SteroidReceptors, Thyroid HormoneTranscription Factor AP-1Transcription Factors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT03941496ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.